Dry powder formulations of epinephrine and associated methods
AssigneeBelhaven BioPharma Inc.
InventorsScott Lyman, Barry Bleske, Ted William Lanpher
Life of this patent
Estimating the term…
Abstract
Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.
Claims20
A method for intranasal administration of a dry powder pharmaceutical composition comprising:
- providing an intranasal device to a patient suffering from anaphylaxis, wherein the intranasal device includes a delivery head and a reservoir containing a dose of the dry powder pharmaceutical composition, wherein the dry powder pharmaceutical composition comprises:
- a first active ingredient, wherein the first active ingredient comprises epinephrine or a pharmaceutically acceptable salt thereof;
- a second active ingredient;
- and
- a carrier;
- actuating the intranasal device to deliver the dose of the dry powder pharmaceutical composition into a nasal cavity of the patient.
A method for intranasal administration of a dry powder pharmaceutical composition comprising:
- providing an intranasal device to a patient suffering from anaphylaxis, wherein the intranasal device includes a delivery head and a reservoir containing a dose of the dry powder pharmaceutical composition, wherein the dry powder pharmaceutical composition comprises:
- at least one active ingredient, wherein the at least one active ingredient comprises about 0.01 mg to about 10 mg of epinephrine or a pharmaceutically acceptable salt thereof;
- and
- a carrier;
- actuating the intranasal device to deliver the dose of the dry powder pharmaceutical composition into a nasal cavity of the patient.
A method for intranasal administration of a dry powder pharmaceutical composition comprising:
- intranasally administering a single dose of a dry powder pharmaceutical composition, wherein the dry powder pharmaceutical composition comprises:
- a first active ingredient, wherein the first active ingredient comprises about 0.01 mg to about 10 mg of epinephrine or a pharmaceutically acceptable salt thereof;
- a second active ingredient;
- and
- a carrier.
Dependencies are inferred from the claim text.